StemCell Therapy

By Nonie Arora

Medicine is about more than difficult diagnoses and cutting-edge research. Research and treatments often raise tricky moral questions.

Jeremy Sugarman Credit: Berman Institute for Bioethics

Dr. Jeremy Sugarman, the founding director for the Trent Center for Bioethics, returned to campus last week to give a talk on the ethics of stem cell research and treatment for the Humanities in Medicine Lecture Series.

Stem cells are a hot topic that have captured the imagination of people around the world, he said.

Is it better to use leftover embryos from IVF or to create them for research? Sugarman asked. He said there is little consensus on this issue, and the question remains whether there is a moral distinction between discarded embryos or those created for research purposes. There is also the thorny issue of whether it is morally acceptable to destroy embryos to create human embryonic stem cells, said Sugarman, who is now at the Berman Institute for Bioethics at Johns Hopkins University.

Amidst the controversy surrounding the moral status of embryos, there has also beenscientific controversy within the stem cell field. Sugarman spoke of Hwang Woo-Suk, who claimed to have cloned human embryos and extracted their stem cells. However, his data was fabricated, Sugarman said. Sugarman elicited laughs from the packed audience when he joked about Woo-Suks former title Supreme Scientist of Korea, an honor that was later revoked. The laughter was tempered by the understanding of how unethical it is to fake any research, but especially on this scale. Still, Sugarman says Woo-Suks example serves to show the effectiveness of peer review in realizing false claims.

Human Embryonic Stem Cells. Source: "Follow the Money The Politics of Embryonic Stem Cell Research." Russo E, PLoS Biology Vol. 3/7/2005, e234 http://dx.doi.org/10.1371/journal.pbio.0030234

Another issue many people are concerned about are chimeras organisms that have parts from two different genetic lines. Already, bone marrow transplants create human-to-human chimeras, Sugarman explained. Some people have qualms about combining materials from human and non-human animals.

Other countries differ from the U.S. in policies on what can be done with human embryonic stem cells. For instance, in Germany it is a criminal offense to destroy an embryo to create a human embryonic stem cell line. It is also illegal for a German citizen to do such work abroad, Sugarman said. He brought up this point to illustrate why local oversight within academic institutions is necessary to not only make sure that research is ethically and scientifically sound but to also be certain that researchers are being protected.

See the original post:
Stem Cells' Tricky Questions

15:48 Russia further delays delivery of Admiral Gorshkov to India:Russia has delayed delivery of a trouble-plagued aircraft carrier for at least a year on Friday, a blow to India's efforts to quickly build up naval strength as increasingly assertive Asian rival China expands its maritime reach. Read 15:47 Attack on teenage girl exposed extremist mindset in Pak: Kayani: In other news: A day after a teenage rights activist was shot in the head by Taliban militants, Pakistan Army Chief Gen Ashfaq Parvez Kayani today condemned the attack on the girl as a "heinous act of terrorism" and warned that it had exposed the "extremist mindset" confronting the country.

Kayani visited a military hospital in Peshawar to meet 14-year-old schoolgirl Malala Yousufzai, who was shot and seriously injured by the militants during an attack yesterday in the former Taliban stronghold of Swat, located 160 km from Islamabad. T

he powerful army chief used the occasion to send out a message to the militants, saying incidents like the attack on Malala "clearly expose the extremist mindset the nation is facing." Kayani said the terrorists had underestimated the "resolve and resilience" of the people.

15:43 The Nobel Prizes were established in the will of 19th century Swedish industrialist Alfred Nobel, the inventor of dynamite. Each award is worth 8 million kronor, or about $1.2 million. The awards are always handed out on Dec. 10, the anniversary of Nobel's death in 1896, writes the NYT.

About half of all medications act on these receptors, so learning about them will help scientists to come up with better drugs.

The Nobel week started Monday with the medicine prize going tostem cellpioneers John Gurdon of Britain and Japan's Shinya Yamanaka. Frenchman Serge Haroche and American David Wineland won the physics prize Tuesday for work on quantum particles.

15:38 The Royal Swedish Academy of Sciences cited the two researchers for studies of G-protein-coupled receptors.'

15:26 Two Americans share Nobel prize for chemistry: Nobel Prize in Chemistry has been awarded jointly to Americans Robert J. Lefkowitz and Brian K. Kobilka. Details in a bit.

"Out of the total affected population of 4.89 million, the number of children was 1.8 million and many of them were affected twice," 'Save the Children' Chief Executive Officer Thomas Chandy said after visiting some flood affected areas yesterday.

In any emergency in any part of the world, children were the worst sufferers and they were unable to deal with the hardship caused by displacement, lack of food and clean water, he said.

Read the original here:
Live! Two Americans share Nobel prize for chemistry

PARIS--(BUSINESS WIRE)--

Regulatory News:

Cellectis (ALCLS.PA) (ALCLS.PA), the French genome engineering specialist, considers the award of the Nobel Prize fin Medicine to Professor Shinya Yamanaka as the validation of its stem cell strategy and is a major growth driver for this activity.

Since 2010 Cellectis started collaborating with Professor Shinya Yamanaka at the Center for iPS Cell Research and Application (CiRA) at Kyoto, Japan, working together on genome engineering of induced pluripotent stem (iPS) cells.

Since then, Cellectis has successively:

Cellectis already sells cellular models for research and drug development within pharmaceutical industry, implementing technologies developed by CiRA. In addition, Cellectis is currently working on a number of develops large-scale projects based on iPS cell technology with two aims:

Andr Choulika, CEO of Cellectis, declares: "the quality of relations between the teams of CiRA and Cellectis Group - based on mutual respect of their scientific expertise on the one hand, the recognition of the strong complementarity of their knowledge on the other - involved the establishment of a real alliance able to compete with the American presence in the area."

Cellectis plans to expand and deepen this collaboration with Prof. Yamanaka in order to strengthen its position as an industry leader, increase its activity remaining at the forefront of iPS cell technology, and develop industry standards in regenerative medicine.

About Cellectis

Founded in France in 1999, the Cellectis Group is based on a highly specific DNA engineering technology. Its application sectors are human health, agriculture and bio-energies. Co-created by Andr Choulika, its Chief Executive Officer, Cellectis is today one of the world leading companies in the field of genome engineering. The Group has a workforce of 230 employees working on 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, St Paul (Minnesota) & Cambridge (Massachusetts) in the United States. Cellectis achieved in 2011 16M revenues and has signed more than 80 industrial agreements with pharmaceutical laboratories, agrochemical and biotechnology companies since its inception. AFM, Dupont, BASF, Bayer, Total, Limagrain, Novo Nordisk are some of the Groups clients and partners.

Go here to see the original:
Cellectis: the Award of Nobel Prize in Medicine to Professor Yamanaka Confirms the Relevance of the Group's Stem Cell ...

Kyodo / Reuters

Kyoto University Professor Shinya Yamanaka (left) and John Gurdon of the Gurdon Institute in Cambridge, England, at a symposium on induced pluripotent stem cells in Tokyo in April 2008

In a testament to the revolutionary potential of the field of regenerative medicine, in which scientists are able to create and replace any cells that are at fault in disease, the Nobel Prize committee on Monday awarded the 2012 Nobel in Physiology or Medicine to two researchers whose discoveries have made such cellular alchemy possible.

The prize went to John B. Gurdon of the University of Cambridge in England, who was among the first to clone an animal, a frog, in 1962, and to Shinya Yamanaka of Kyoto University in Japan who in 2006 discovered the four genes necessary to reprogram an adult cell back to an embryonic state.

Sir John Gurdon, who is now a professor at an institute that bears his name, earned the ridicule of many colleagues back in the 1960s when he set out on a series of experiments to show that the development of cells could be reversed. At the time, biologists knew that all cells in an embryo had the potential to become any cell in the body, but they believed that once a developmental path was set for each cell toward becoming part of the brain, or a nerve or muscle it could not be returned to its embryonic state. The thinking was that as a cell developed, it would either shed or silence the genes it no longer used, so that it would be impossible for a cell from an adult animal, for example, to return to its embryonic state and make other cells.

(MORE: Stem Cell Miracle? New Therapies May Cure Chronic Conditions Like Alzheimers)

Working with frogs, Gurdon proved his critics wrong, showing that some reprogramming could occur. Gurdon took the DNA from a mature frogs gut cell and inserted it into an egg cell. The resulting egg, when fertilized, developed into a normal tadpole, a strong indication that the genes of the gut cell were amenable to reprogramming; they had the ability to function as more than just an intestinal cell, and could give rise to any of the cells needed to create an entirely new frog.

Just as Gurdon was facing his critics in England, a young boy was born in Osaka, Japan, who would eventually take Gurdons finding to unthinkable extremes. Initially, Shinya Yamanaka would follow his fathers wishes and become an orthopedic surgeon, but he found himself ill-suited to the surgeons life. Intrigued more by the behind-the-scenes biological processes that make the body work, he found himself drawn to basic research, and began his career by trying to find a way to lower cholesterol production. That work also wasnt successful, but it drew him to the challenge of understanding what makes cells divide, proliferate and develop in specific ways.

In 2006, while at Kyoto University, Yamanaka stunned scientists by announcing he had successfully achieved what Gurdon had with the frog cells, but without using eggs at all. Yamanaka mixed four genes in with skin cells from adult mice and turned those cells back to an embryo-like state, essentially erasing their development and turning back their clock. The four genes reactivated other genes that are prolific in the early embryo, and turned off those that directed the cells to behave like skin.

(MORE: Ovary Stem Cells Can Produce New Human Eggs)

See original here:
Stem Cell Scientists Awarded Nobel Prize in Physiology and Medicine

08-10-2012 20:30 England's Sir John Gurdon and Dr. Shinya Yamanaka from Japan share the 2012 Nobel Prize in medicine for work on stem cells, revealing that mature cells can be reverted into primitive cells. Ray Suarez talks to Harvard Stem Cell Institute's Dr. David Scadden, who explains the implications and applications for stem cell medicine.

Original post:
Stem Cell Scientists Win Nobel Prize in Medicine - Video

08-10-2012 11:59 The Japanese scientist who managed to transform mature cells into stem cells, without destroying embryos, has been awarded a Nobel Prize in Medicine. Shinya Yamanaka was awarded along with John B. Gurdon from Britain.

See more here:
Yamanaka awarded Nobel Prize in Medicine for work with stem cells - Video

STOCKHOLM (Reuters) - Scientists from Britain and Japan shared the Nobel Prize in Medicine on Monday for the discovery that adult cells can be reprogrammed back into stem cells which can turn into any kind of tissue and may one day repair damaged organs.

John Gurdon, 79, of the Gurdon Institute in Cambridge, Britain and Shinya Yamanaka, 50, of Kyoto University in Japan, discovered ways to create tissue that would act like embryonic cells, without the need to harvest embryos. They share the $1.2 million prize equally.

"These groundbreaking discoveries have completely changed our view of the development and specialisation of cells," the Nobel Assembly at Stockholm's Karolinska Institute said in a statement.

The big hope for stem cells is that they can be used to replace damaged tissues in everything from spinal cord injuries to Parkinson's disease.

All of the tissue in the body starts as stem cells, before developing into mature skin, blood, nerves, muscle and bone.

Scientists once thought it was impossible to turn adult tissue back into stem cells, which meant that new stem cells could only be created by harvesting embryos. But Yamanaka and Gurdon showed that development can be reversed, turning adult cells back into cells that behave like embryos.

With "induced pluripotency stem cells", or iPS cells, ordinary skin or blood cells from adults are transformed back into stem cells which doctors hope will be able to repair damaged organs without being rejected by the immune system.

There are concerns, however, that iPS cells could grow out of control and develop into tumours.

"The eventual aim is to provide replacement cells of all kinds," Gurdon's Institute explains on its website.

"We would like to be able to find a way of obtaining spare heart or brain cells from skin or blood cells. The important point is that the replacement cells need to be from the same individual, to avoid problems of rejection and hence of the need for immunosuppression."

See the original post here:
UK, Japan scientists win Nobel for stem cell breakthroughs

STOCKHOLM - Scientists from Britain and Japan shared a Nobel Prize on Monday for the discovery that adult cells can be transformed back into embryo-like stem cells that may one day regrow tissue in damaged brains, hearts or other organs.

John Gurdon, 79, of the Gurdon Institute in Cambridge, Britain and Shinya Yamanaka, 50, of Kyoto University in Japan, discovered ways to create tissue that would act like embryonic cells, without the need to collect the cells from embryos.

They share the $1.2 million Nobel Prize for Medicine, for work Gurdon began 50 years ago and Yamanaka capped with a 2006 experiment that transformed the field of "regenerative medicine" - the search for ways to cure disease by growing healthy tissue.

"These groundbreaking discoveries have completely changed our view of the development and specialization of cells," the Nobel Assembly at Stockholm's Karolinska Institute said.

All of the body starts as stem cells, before developing into tissue like skin, blood, nerves, muscle and bone. The big hope is that stem cells can grow to replace damaged tissue in cases from spinal cord injuries to Parkinson's disease.

Scientists once thought it was impossible to turn adult tissue back into stem cells. That meant new stem cells could only be created by taking them from embryos, which raised ethical objections that led to research bans in some countries.

As far back as 1962 Gurdon became the first scientist to clone an animal, making a healthy tadpole from the egg of a frog with DNA from another tadpole's intestinal cell. That showed that developed cells carry the information to make every cell in the body - decades before other scientists made world headlines by cloning the first mammal from adult DNA, Dolly the sheep.

More than 40 years later, Yamanaka produced mouse stem cells from adult mouse skin cells by inserting a small number of genes. His breakthrough effectively showed that the development that takes place in adult tissue could be reversed, turning adult tissue back into cells that behave like embryos.

Stem cells created from adult tissue are known as "induced pluripotency stem cells", or iPS cells. Because patients may one day be treated with stem cells from their own tissue, their bodies might be less likely to reject them.

"The eventual aim is to provide replacement cells of all kinds," Gurdon's institute explains on its website.

Read this article:
UK, Japan scientists win Nobel for adult stem cell discovery

NEW YORK (AP) Two scientists from different generations won the Nobel Prize in medicine Monday for the groundbreaking discovery that cells in the body can be reprogrammed into completely different kinds, work that reflects the mechanism behind cloning and offers an alternative to using embryonic stem cells.

The work of British researcher John Gurdon and Japanese scientist Shinya Yamanaka who was born the year Gurdon made his discovery holds hope for treating diseases like Parkinson's and diabetes by growing customized tissue for transplant.

And it has spurred a new generation of laboratory studies into other illnesses, including schizophrenia, which may lead to new treatments.

Basically, Gurdon, 79, and Yamanaka, 50, showed how to make the equivalent of embryonic stem cells without the ethical questions those very versatile cells pose, a promise scientists are now scrambling to fulfill.

Once created, these "blank slate" cells can be nudged toward developing into other cell types. Skin cells can ultimately be transformed into brain cells, for example.

Just last week, scientists reported turning skin cells from mice into eggs that produced baby mice, a possible step toward new fertility treatments.

Gurdon and Yamanaka performed "courageous experiments" that challenged scientific opinion, said Doug Melton, co-director of the Harvard Stem Cell Institute.

"Their work shows ... that while cells might be specialized to do one thing, they have the potential to do something else," Melton said. It "really lays the groundwork for all the excitement about stem cell biology."

Another Harvard stem cell researcher, Dr. George Daley said, "I don't think anybody is surprised" by the award announcement. "The fact that these two share it together is inspired."

In announcing the $1.2 million award, the Nobel committee at Stockholm's Karolinska Institute said the work has "revolutionized our understanding of how cells and organisms develop."

Here is the original post:
Nobel awarded for stem cell, early cloning work

NEW YORK (AP) Two scientists from different generations won the Nobel Prize in medicine Monday for the groundbreaking discovery that cells in the body can be reprogrammed into completely different kinds, work that reflects the mechanism behind cloning and offers an alternative to using embryonic stem cells.

The work of British researcher John Gurdon and Japanese scientist Shinya Yamanaka who was born the year Gurdon made his discovery holds hope for treating diseases like Parkinsons and diabetes by growing customized tissue for transplant.

And it has spurred a new generation of laboratory studies into other illnesses, including schizophrenia, which may lead to new treatments.

Basically, Gurdon, 79, and Yamanaka, 50, showed how to make the equivalent of embryonic stem cells without the ethical questions those very versatile cells pose, a promise scientists are now scrambling to fulfill.

Once created, these blank slate cells can be nudged toward developing into other cell types. Skin cells can ultimately be transformed into brain cells, for example.

Just last week, scientists reported turning skin cells from mice into eggs that produced baby mice, a possible step toward new fertility treatments.

Gurdon and Yamanaka performed courageous experiments that challenged scientific opinion, said Doug Melton, co-director of the Harvard Stem Cell Institute.

Their work shows ... that while cells might be specialized to do one thing, they have the potential to do something else, Melton said. It really lays the groundwork for all the excitement about stem cell biology.

Another Harvard stem cell researcher, Dr. George Daley said, I dont think anybody is surprised by the award announcement. The fact that these two share it together is inspired.

In announcing the $1.2 million award, the Nobel committee at Stockholms Karolinska Institute said the work has revolutionized our understanding of how cells and organisms develop.

Read the original:
2 scientists win nobel for research

Two scientists were awarded the Nobel Prize in medicine Monday for their discovery and work with stem cells cells that can be programmed to develop into different types of cells that can serve different functions in the body.

Stem cells place in research particularly human embryonic stem cells have been a topic of political debate since their discovery in 1962 by one of the winners of the Prize, British scientist John Gurdon.

The second part of the prize was awarded to Shinya Yamanaka, who with his graduate student showed that a stem cell could be created from an already-specialized cell that can be changed to perform with functions other than their original meaning that embryos are not necessarily needed.

But stem cell discoveries should be lauded for their advancement of science and medicine, instead of being used for political gain or intertwined with religious rulings, as is inevitable during each election season, and thanks to these recent discoveries that dont require embryonic stem cells, hopefully the merit of these cells can stand alone.

The topic has been mostly muted at the national level save for a few debates between Senate candidates in Connecticut last weekend but the latest Nobel Prize should bring to light recent research that has shown there are ways to obtain stem cells other than from fetuses, restoring trust in ongoing research to find new ways to create and utilize the cells.

Though research funded by the National Institutes of Health already cannot use stem cells derived from human embryos, unless the cells have been provided by a private entity that is not funded with government money, as enacted by an executive order after President Barack Obama entered office, the new discovery keeps politics out of science and U.S. scientists can remain on par with those in other nations, continuing their work to find medical solutions to diseases such as Alzheimers and cancer.

According to the Huffington Post, since Obamas order, stem cell research has fueled work including restoring hearing loss, certain types of blindness and regenerating spine nerve cells.

With talk likely to flare up after this prizes announcement, it is important to keep in mind the medical advances instead of the political or moral judgments that can be made when stem cell studies are allowed.

More:
Stem cell research and politics must be separated

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dsn5rh/cancer_stem_cells) has announced the addition of the "Cancer Stem Cells Drug Pipeline Update 2012" report to their offering.

There are today 203 companies plus partners developing 243 cancer stem cells and developmental pathways drugs in 684 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 123 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. These targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.

Drug Pipeline Update at a Glance

Investigators

Includes more than 203 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.

Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.

Drug name & Synonyms

Lists commercial, generic and code names for drugs.

Developmental stage

Here is the original post:
Research and Markets: Cancer Stem Cells Drug Pipeline Update 2012 Includes More Than 203 Principal Investigators plus ...

Thomas Perlmann of Karolinska Institute presents Sir John B. Gurdon of Britain and Shinya Yamanaka of Japan as winners of the 2012 Nobel Prize in medicine or physiology. The prize committee at Stockholms Karonlinska institute said the discovery has revolutionized our understanding of how cells and organisms develop. Photograph by Bertil Enevag Ericson/Scanpix/AP Photo

Stem cells derived from a mouses skin won Shinya Yamanaka the Nobel Prize yesterday. Now researchers in Japan are seeking to use his pioneering technology for an even greater prize: restoring sight.

Scientists at the Riken Center for Developmental Biology in Kobe plan to use so-called induced pluripotent stem cells in a trial among patients with macular degeneration, a disease in which the retina becomes damaged, resulting in loss of vision, Yamanaka told reporters in San Francisco yesterday.

Companies including Pfizer Inc. (PFE) are already planning trials of stem cells derived from human embryos. The Japanese study will be the first to use a technology that mimics the power of embryonic cells while avoiding the ethical controversy that accompanies them.

The work in that area looks very encouraging, John B. Gurdon, 79, a professor at the University of Cambridge who shared the Nobel with Yamanaka yesterday, said in an interview in London.

Yamanaka and Gurdon shared the 8 million Swedish kronor ($1.2 million) award for experiments 50 years apart that showed that mature cells retain in latent form all the DNA they had as immature stem cells, and that they can be returned to that potent state, offering the potential for a new generation of therapies against hard-to-treat diseases such as macular degeneration.

In a study published in 1962, Gurdon took a cell from a tadpoles gut, extracted the nucleus, and inserted it into the egg cell of an adult frog whose own nucleus had been removed. That reprogrammed egg cell developed into a tadpole with the genetic characteristics of the original tadpole, and subsequent trials yielded adult frogs.

Yamanaka, 50, a professor at Kyoto University, built on Gurdons work by adding four genes to a mouse skin cell, returning it to its immature state as a stem cell with the potential to become any cell in the body. He dubbed them induced pluripotent stem cells.

There are few moments in science that are undisputed as genuine elegant creativity and simplicity, Alan Trounson, the president of the California Institute for Regenerative Medicine in San Francisco, said in an e-mail. Shinya Yamanaka is responsible for one of those. An extraordinary accomplishment by a genuinely modest and brilliant scientist.

The technology may lead to new treatments against diseases such as Parkinsons by providing replacement cells.

The rest is here:
Nobel Winner’s Stem Cells to Be Tested in Eye Disease Next Year

Imagine the horror of a soldier losing a limb on the battlefield, or a loved one having a body part amputated due to diabetes. But, what if they could restore their limbs by activating their stem cells?

New Mexico State University biologist Graciela Unguez and a team of researchers found that electric fish, a vertebrate animal just like humans, can regenerate their tails following amputation after activating their stem cells. The findings were published in the May 2012 edition of the scientific journal, PLOS One.

"What's surprising is that as humans, we're one of the few animal species that do not readily regenerate limbs, organs or most tissues," Unguez said. "So, there's a lot of interest in how these fish do it, and what's preventing us from doing it."

Regeneration is the process of restoring lost cells, tissues or organs. According to Unguez, most animals have the ability to regenerate eyes and tails and some animals may be able to regenerate up to half of their bodies.

The researchers discovered that when they cut off up to one third of an electric fish's tail, including the spinal cord, vertebrae, muscles, skin, connective tissues and nerves, the fish would regenerate it. Unguez said the more tissue cut off, the longer the regeneration takes, but for the purpose of her study, it takes about three weeks.

"It's really exciting to us because, here's an example of an animal that can regenerate a lot of tissue types that are also found in humans," Unguez said. "So it puts into question this previous idea that those animals that can regenerate losses of many tissues do it because they do it differently than humans."

Unguez has used the electric fish as a model system to investigate the role that the nervous system plays in the fate of electrically excitable cells like muscle cells for 15 years. She noted that for many years, scientists have thought that highly regenerative animals use a mechanism of regeneration that does not involve stem cells, and this stem cell-based mechanism is well known in humans. In contrast, the stem cell-independent mechanism found in highly regenerative animals is not normally active in humans.

Unguez explained that stem cells are a small population of cells that do not mature and stay with us throughout our life, and then when called upon, they reenter the cell cycle to become muscle cells, neurons, skill cells and such.

But, what Unguez and her collaborators discovered was the opposite. The electric fish actually activated its own muscle and electric organ stem cells to regenerate. She said the adult fish regenerated unendingly with the activation of their stem cells.

"It does not negate other mechanisms, but it definitely showed that it was largely due to an activation of stem cells, just like humans have," Unguez said. "So maybe it's not as far apart, maybe some of the mechanisms involved or the events that need to be activated are more closely related than we thought."

See the original post:
Electric fish at NMSU activate stem cells for regeneration

8 October 2012 Last updated at 22:25 ET By Regan Morris BBC News, Los Angeles

US researchers say they will redouble their efforts to create human sperm from stem cells following the success of a Japanese study involving mice.

A Kyoto University team used mice stem cells to create eggs, which were fertilised to produce baby mice.

Dr Renee Pera, of Stanford University in California, aims to create human sperm to use for reproduction within two years, and eggs within five years.

Infertility affects up to 15% of reproductive-aged couples worldwide.

"I know people think it's Frankenstein medicine, but I think it's not an imagined or lessened health problem - infertility affects your whole life," Dr Pera says.

"To have sex and have a baby would be a super simple decision, but not everybody can do it."

But using embryonic stem cells for research - as Dr Pera's lab at the Institute for Stem Cell Biology and Regenerative Medicine does - is controversial because the embryos are destroyed in order to use them.

Dr Pera's lab uses embryos left over from IVF treatments.

Stem cells have the potential to grow into any cell in the body. Creating eggs in a lab could become mainstream, much like IVF is viewed today.

View original post here:
US team aim to make human sperm

HONG KONG (Reuters) - Nobel laureate Shinya Yamanaka warned patients on Tuesday about unproven "stem cell therapies" offered at clinics and hospitals in a growing number of countries, saying they were highly risky.

The Internet is full of advertisements touting stem cell cures for just about any disease -- from diabetes, multiple sclerosis, arthritis, eye problems, Alzheimer's and Parkinson's to spinal cord injuries -- in countries such as China, Mexico, India, Turkey and Russia.

Yamanaka, who shared the Nobel Prize for Medicine on Monday with John Gurdon of the Gurdon Institute in Cambridge, Britain, called for caution.

"This type of practice is an enormous problem, it is a threat. Many so-called stem cell therapies are being conducted without any data using animals, preclinical safety checks," said Yamanaka of Kyoto University in Japan.

"Patients should understand that if there are no preclinical data in the efficiency and safety of the procedure that he or she is undergoing ... it could be very dangerous," he told Reuters in a telephone interview.

Yamanaka and Gurdon shared the Nobel Prize for the discovery that adult cells can be transformed back into embryo-like stem cells that may one day regrow tissue in damaged brains, hearts or other organs.

"I hope patients and lay people can understand there are two kinds of stem cell therapies. One is what we are trying to establish. It is solely based on scientific data. We have been conducting preclinical work, experiments with animals, like rats and monkeys," Yamanaka said.

"Only when we confirm the safety and effectiveness of stem cell therapies with animals will we initiate clinical trials using a small number of patients."

Yamanaka, who calls the master stem cells he created "induced pluripotent stem cells" (iPS), hopes to see the first clinical trials soon.

Read more:
The next frontier in stem cell treatments: phony therapies

By Tan Ee Lyn

HONG KONG (Reuters) - Nobel laureate Shinya Yamanaka warned patients on Tuesday about unproven "stem cell therapies" offered at clinics and hospitals in a growing number of countries, saying they were highly risky.

The Internet is full of advertisements touting stem cell cures for just about any disease -- from diabetes, multiple sclerosis, arthritis, eye problems, Alzheimer's and Parkinson's to spinal cord injuries -- in countries such as China, Mexico, India, Turkey and Russia.

Yamanaka, who shared the Nobel Prize for Medicine on Monday with John Gurdon of the Gurdon Institute in Cambridge, Britain, called for caution.

"This type of practice is an enormous problem, it is a threat. Many so-called stem cell therapies are being conducted without any data using animals, preclinical safety checks," said Yamanaka of Kyoto University in Japan.

"Patients should understand that if there are no preclinical data in the efficiency and safety of the procedure that he or she is undergoing ... it could be very dangerous," he told Reuters in a telephone interview.

Yamanaka and Gurdon shared the Nobel Prize for the discovery that adult cells can be transformed back into embryo-like stem cells that may one day regrow tissue in damaged brains, hearts or other organs.

"I hope patients and lay people can understand there are two kinds of stem cell therapies. One is what we are trying to establish. It is solely based on scientific data. We have been conducting preclinical work, experiments with animals, like rats and monkeys," Yamanaka said.

"Only when we confirm the safety and effectiveness of stem cell therapies with animals will we initiate clinical trials using a small number of patients."

Yamanaka, who calls the master stem cells he created "induced pluripotent stem cells" (iPS), hopes to see the first clinical trials soon.

More here:
Nobel laureate Yamanaka warns of rogue "stemcell therapies"

Nobel laureate Shinya Yamanaka warned patients on Tuesday about unproven "stem cell therapies" offered at clinics and hospitals in a growing number of countries, saying they were highly risky.

The Internet is full of advertisements touting stem cell cures for just about any disease -- from diabetes, multiple sclerosis, arthritis, eye problems, Alzheimer's and Parkinson's to spinal cord injuries -- in countries such as China, Mexico, India, Turkey and Russia.

Yamanaka, who shared the Nobel Prize for Medicine on Monday with John Gurdon of the Gurdon Institute in Cambridge, Britain, called for caution.

"This type of practice is an enormous problem, it is a threat. Many so-called stem cell therapies are being conducted without any data using animals, preclinical safety checks," said Yamanaka of Kyoto University in Japan.

"Patients should understand that if there are no preclinical data in the efficiency and safety of the procedure that he or she is undergoing ... it could be very dangerous," he told Reuters in a telephone interview.

Yamanaka and Gurdon shared the Nobel Prize for the discovery that adult cells can be transformed back into embryo-like stem cells that may one day regrow tissue in damaged brains, hearts or other organs.

"I hope patients and lay people can understand there are two kinds of stem cell therapies. One is what we are trying to establish. It is solely based on scientific data. We have been conducting preclinical work, experiments with animals, like rats and monkeys," Yamanaka said.

"Only when we confirm the safety and effectiveness of stem cell therapies with animals will we initiate clinical trials using a small number of patients."

Yamanaka, who calls the master stem cells he created "induced pluripotent stem cells" (iPS), hopes to see the first clinical trials soon.

"There is much promising research going on," he said.

Read more:
Nobel prize winner in medicine warns of rogue 'stem cell therapies'

John Gurdon and Shinya Yamanaka were jointly awarded the Nobel Prize in Physiology or Medicine on Monday for their research on resetting cells to their earliest developmental stages.The work has yet to yield a clear breakthrough in medical treatment, but it has revolutionized scientists ability to study both normal and diseased development.

Gurdon, 79, performed his seminal work in the late 1950s and early 1960sa good deal of it before Yamanaka was born. In his most famous study, Gurdon showed that replacing the nucleus of an adult cell with the nucleus of an embryonic cell reset the adult cell to an embryonic state: Many of the cells became tadpoles. This strongly suggested that embryonic-state DNA and the molecules that controlled gene expression in the nucleus were sufficient to make a cell "pluripotent" againor capable of turning into any type of tissue in the body.

Some40 years later, Yamanaka took this further by showing that adult mouse skin cells could be reset to their embryonic state just by adding a set of genes into the cells nuclei, and he later reduced this number to just four genes. The cells are now referred to as induced pluripotent stem cells, or iPS cells, and are a common tool in the study of development and disease.

With Yamanakas discovery, researchers suddenly had a way of studying pluripotent stem cells without destroying embryosa limitation that had caused countless headaches at the time of Yamanakas breakthrough, as President George W. Bush had instituted severe limitations on such research.

Since Yamanakas seminal finding, researchers have used the approach to demonstrate some stunning feats: They have turned the skin cells of people who have Parkinsons disease into disease in a dish models that allow them to watch the development of the disease over time and to observe what genes go wrong when and why, and, just last week, a team of scientists published research that used the approach to turn mouse skin cells back into mouse eggs, which then produced baby mice.

The technique has not been without complications: Because one of the four genes is also highly implicated in cancer, the iPS cells are more likely to become cancerous than true embryonic stem cells. The issue has slowed research in the field.

Today, Gurdon works at the Gurdon Institute in Cambridge, England, which he founded, and Yamanaka has appointments at UC San Franciscos Gladstone Institute and at Kyoto University.

You can read all about the winners here.

Return to the Science Now blog.

Go here to read the rest:
Nobel Prize goes to pioneers of induced stem cell research

Kyodo / Reuters

Kyoto University Professor Shinya Yamanaka (left) and John Gurdon of the Gurdon Institute in Cambridge, England, at a symposium on induced pluripotent stem cells in Tokyo in April 2008

In a testament to the revolutionary potential of the field of regenerative medicine, in which scientists are able to create and replace any cells that are at fault in disease, the Nobel Prize committee on Monday awarded the 2012 Nobel in Physiology or Medicine to two researchers whose discoveries have made such cellular alchemy possible.

The prize went to John B. Gurdon of the University of Cambridge in England, who was among the first to clone an animal, a frog, in 1962, and to Shinya Yamanaka of Kyoto University in Japan who in 2006 discovered the four genes necessary to reprogram an adult cell back to an embryonic state.

Sir John Gurdon, who is now a professor at an institute that bears his name, earned the ridicule of many colleagues back in the 1960s when he set out on a series of experiments to show that the development of cells could be reversed. At the time, biologists knew that all cells in an embryo had the potential to become any cell in the body, but they believed that once a developmental path was set for each cell toward becoming part of the brain, or a nerve or muscle it could not be returned to its embryonic state. The thinking was that as a cell developed, it would either shed or silence the genes it no longer used, so that it would be impossible for a cell from an adult animal, for example, to return to its embryonic state and make other cells.

(MORE: Stem Cell Miracle? New Therapies May Cure Chronic Conditions Like Alzheimers)

Working with frogs, Gurdon proved his critics wrong, showing that some reprogramming could occur. Gurdon took the DNA from a mature frogs gut cell and inserted it into an egg cell. The resulting egg, when fertilized, developed into a normal tadpole, a strong indication that the genes of the gut cell were amenable to reprogramming; they had the ability to function as more than just an intestinal cell, and could give rise to any of the cells needed to create an entirely new frog.

Just as Gurdon was facing his critics in England, a young boy was born in Osaka, Japan, who would eventually take Gurdons finding to unthinkable extremes. Initially, Shinya Yamanaka would follow his fathers wishes and become an orthopedic surgeon, but he found himself ill-suited to the surgeons life. Intrigued more by the behind-the-scenes biological processes that make the body work, he found himself drawn to basic research, and began his career by trying to find a way to lower cholesterol production. That work also wasnt successful, but it drew him to the challenge of understanding what makes cells divide, proliferate and develop in specific ways.

In 2006, while at Kyoto University, Yamanaka stunned scientists by announcing he had successfully achieved what Gurdon had with the frog cells, but without using eggs at all. Yamanaka mixed four genes in with skin cells from adult mice and turned those cells back to an embryo-like state, essentially erasing their development and turning back their clock. The four genes reactivated other genes that are prolific in the early embryo, and turned off those that directed the cells to behave like skin.

(MORE: Ovary Stem Cells Can Produce New Human Eggs)

See more here:
Stem Cell Scientists Awarded Nobel Prize in Physiology and Medicine